Clinical Trial

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-09-09; most recent amendment 2026-07-24.
Status change: Not Yet Recruiting → Recruiting 2025-01-27
Trial Details
NCT Number NCT06593431
Lead Sponsor M.D. Anderson Cancer Center
Conditions Pancreas Cancer, Oligometastatic
Enrollment 80 participants
Start Date 2024-10-23
Primary Completion 2029-06-29 (estimated)
Study Completion 2029-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-27